Paving the path toward multi-omics approaches in the diagnostic challenges faced in thyroid pathology
Authors:
- 29 November 2023
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Proteomics
- Vol. 20 (12) , 419-437
Abstract
IntroductionDespite advancements in diagnostic methods, the classification of indeterminate thyroid nodules still poses diagnostic challenges not only in pre-surgical evaluation but even after histological evaluation of surgical specimens. Proteomics, aided by mass spectrometry and integrated with artificial intelligence and machine learning algorithms, shows great promise in identifying diagnostic markers for thyroid lesions.Areas coveredThis review provides in-depth exploration of how proteomics has contributed to the understanding of thyroid pathology. It discusses the technical advancements related to immunohistochemistry, genetic and proteomic techniques, such as mass spectrometry, which have greatly improved sensitivity and spatial resolution up to single-cell level. These improvements allowed the identification of specific protein signatures associated with different types of thyroid lesions.Expert commentaryAmong all the proteomics approaches, spatial proteomics stands out due to its unique ability to capture the spatial context of proteins in both cytological and tissue thyroid samples. The integration of multi-layers of molecular information combining spatial proteomics, genomics, immunohistochemistry or metabolomics and the implementation of artificial intelligence and machine learning approaches, represent hugely promising steps forward toward the possibility to uncover intricate relationships and interactions among various molecular components, providing a complete picture of the biological landscape whilst fostering thyroid nodule diagnosis.Keywords
Funding Information
- Regione Lombardia (regional law n° 9/2020)
- National Plan for NRRP Complementary Investments
- European Commission
This publication has 153 references indexed in Scilit:
- Diagnostic significance of CK19, RET, galectin-3 and HBME-1 expression for papillary thyroid carcinomaJournal of Clinical Pathology, 2010
- Diagnostic value of decreased expression of CD56 protein in papillary carcinoma of the thyroid glandBasic and Applied Pathology, 2009
- Cytoplasmic and serum galectin-3 in diagnosis of thyroid malignanciesBiochemical and Biophysical Research Communications, 2008
- Combined analysis of galectin-3 and BRAFV600E improves the accuracy of fine-needle aspiration biopsy with cytological findings suspicious for papillary thyroid carcinomaEndocrine-Related Cancer, 2007
- Papillary carcinoma of the thyroid: low expression of NCAM (CD56) is associated with downregulation of VEGF‐D production by tumour cellsThe Journal of Pathology, 2007
- Diagnostic Value of Galectin-3, HBME-1, Cytokeratin 19, High Molecular Weight Cytokeratin, Cyclin D1 and p27kip1 in the Differential Diagnosis of Thyroid NodulesJournal of Korean Medical Science, 2007
- Diagnostic Usefulness of HBME1, Galectin-3, CK19, and CITED1 and Evaluation of Their Expression in Encapsulated Lesions With Questionable Features of Papillary Thyroid CarcinomaAmerican Journal of Clinical Pathology, 2006
- Immunohistochemical markers in diagnosis of papillary thyroid carcinoma: utility of HBME1 combined with CK19 immunostainingLaboratory Investigation, 2006
- Galectins as modulators of tumour progressionNature Reviews Cancer, 2005
- Mutations of the BRAF gene in human cancerNature, 2002